Actionable news
All posts from Actionable news
Actionable news in CYTK: Cytokinetics, Incorporated,

Cytokinetics' (CYTK) CEO Robert Blum on Q3 2015 Results - Earnings Call Transcript


Good afternoon and welcome ladies and gentlemen, to the Cytokinetics’ Third Quarter 2015 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open the call for questions and answers after the presentation. I will now turn the call over to Diane Weiser, Cytokinetics’ Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser - Vice President-Corporate Communications and Investor Relations

Good afternoon and thank you for joining us on this conference call today. Leading today’s call is Robert Blum, our President and Chief Executive Officer. Following Robert’s initial comments, Fady Malik, our Senior Vice President of Research and Development will provide an update on the clinical development program for omecamtiv mecarbil, our first-in-class cardiac myosin activator, which is being developed for the potential treatment of heart failure and the recent announcement regarding results from COSMIC-HF.

Then Andy Wolff, our Senior Vice President and Chief Medical Officer, will provide an update on VITALITY-ALS, our Phase III...